Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which bring fear to the patients，especially for those who cannot tolerate or refuse chemotherapy.Several studies indicated that the strategies of chemo-free ,such as the combination of immunotherapy with antiangiogenic therapy or with SBRT, were safe and well tolerated, without increasing adverse reactions. Both of them have a promising efficacy with a manageable toxicity profile in patients with resectable NSCLC. The investigators aim to assess the activity and safety of neoadjuvant SBRT and immunotherapy plus antiangiogenic therapy in patients with resectable NSCLC.

NCT Number	NCT07231575
Lead Sponsor	Sun Yat-sen University
Conditions	Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy
Enrollment	39 participants
Start Date	2025-11-10
Primary Completion	2027-11-30 (estimated)
Study Completion	2032-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-18